$1.99 -0.06 (-2.93%)

Zura Bio Limited Class A Ordinary Shares (ZURA)

Zura Bio Limited is a biotechnology company focused on developing innovative therapies for immune-mediated diseases. The company engages in the research and development of antibody-based treatments aimed at improving patient outcomes in conditions such as autoimmune and inflammatory disorders.

🚫 Zura Bio Limited Class A Ordinary Shares does not pay dividends

Company News

Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know
Zacks Investment Research • Zacks Equity Research • May 31, 2024

The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Benzinga • Benzinga Insights • October 10, 2023

Upgrades According to RBC Capital, the prior rating for Montrose Environmental Group Inc (NYSE:MEG) was changed from Sector Perform to Outperform. In the second quarter, Montrose Environmental Gr showed an EPS of $0.13, compared to $0.03 from the year-ago quarter. At the moment, the stock has a 52-week-high of $55.00 and a 52-week-low of $26.64. Montrose Environmental Gr closed at $27.76 at the end of the last trading period. For Ameris Bancorp (NASDAQ:ABCB), DA Davidson upgraded the previous rating of Neutral to Buy. For the second quarter, Ameris had an EPS of $0.91, compared to year-ago quarter EPS of $1.18. The stock has a 52-week-high of $54.17 and a 52-week-low of $28.33. At the end of the last trading period, Ameris closed at $38.22. According to B of A Securities, the prior rating for Sabra Health Care REIT Inc (NASDAQ:SBRA) was changed from Neutral to Buy. For the second quarter, Sabra Health Care REIT had an EPS of $0.33, compared to year-ago quarter EPS of $0.39. At the moment, the stock has a 52-week-high of $14.32 and a 52-week-low of $10.08. Sabra Health Care REIT closed at $14.01 at the end of the last trading period. According to B of A Securities, the prior rating for Omega Healthcare Investors Inc (NYSE:OHI) was changed from Neutral to Buy. Omega Healthcare Invts earned $0.74 in the second quarter, compared to $0.76 in the year-ago quarter. The stock has a 52-week-high of $34.13 and a 52-week-low of $25.61. At the end of the last trading period, Omega Healthcare Invts closed at $33.64. B of A Securities upgraded the previous rating for Electronic Arts Inc (NASDAQ:EA) from Neutral to Buy. For the first quarter, Electronic Arts had an EPS of $1.14, compared to year-ago quarter EPS of $0.47. The current stock performance of Electronic Arts shows a 52-week-high of $140.30 and a 52-week-low of $108.53. Moreover, at the end of the last trading period, the closing price was at $124.59. Piper Sandler upgraded the previous rating for Exact Sciences Corp (NASDAQ:EXAS) from Neutral to Overweight. In the second quarter, Exact Sciences showed an EPS of $0.45, compared to $0.90 from the year-ago quarter. The stock has a 52-week-high of $100.77 and a 52-week-low of $29.29. At the end of the last trading period, Exact Sciences closed at $64.46. Jefferies upgraded the previous rating for Pinnacle Financial Partners Inc (NASDAQ:PNFP) from Underperform to Hold. In the second quarter, Pinnacle Finl Partners showed an EPS of $1.79, compared to $1.86 from the year-ago quarter. The stock has a 52-week-high of $89.00 and a 52-week-low of $43.31. At the end of the last trading period, Pinnacle Finl Partners closed at $66.25. For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), JP Morgan upgraded the previous rating of Neutral to Overweight. In the second quarter, ACADIA Pharmaceuticals showed an EPS of $0.01, compared to $0.21 from the year-ago quarter. The current stock performance of ACADIA Pharmaceuticals shows a 52-week-high of $33.99 and a 52-week-low of $13.73. Moreover, at the end of the last trading period, the closing price was at $21.74. According to UBS, the prior rating for Rivian Automotive Inc (NASDAQ:RIVN) was changed from Neutral to Buy. In the second quarter, Rivian Automotive showed an EPS of $1.08, compared to $1.62 from the year-ago quarter. At the moment, the stock has a 52-week-high of $36.44 and a 52-week-low of $11.68. Rivian Automotive closed at $18.78 at the end of the last trading period. See all analyst ratings upgrades. Downgrades According to Barrington Research, the prior rating for StarTek Inc (NYSE:SRT) was changed from Outperform to Market Perform. For the second quarter, StarTek had an EPS of $0.04, compared to year-ago quarter EPS of $0.13. The current stock performance of StarTek shows a 52-week-high of $4.53 and a 52-week-low of $2.64. Moreover, at the end of the last trading period, the closing price was at $3.26. For Netstreit Corp (NYSE:NTST), B of A Securities downgraded the previous rating of Neutral to Underperform. In the second quarter, Netstreit showed an EPS of $0.30, compared to $0.28 from the year-ago quarter. The current stock performance of Netstreit shows a 52-week-high of $20.64 and a 52-week-low of $14.84. Moreover, at the end of the last trading period, the closing price was at $15.20. For Spirit Realty Capital Inc (NYSE:SRC), B of A Securities downgraded the previous rating of Neutral to Underperform. Spirit Realty Cap earned $0.91 in the second quarter, compared to $0.90 in the year-ago quarter. The stock has a 52-week-high of $44.65 and a 52-week-low of $32.48. At the end of the last trading period, Spirit Realty Cap closed at $33.59. For Realty Income Corp (NYSE:O), B of A Securities downgraded the previous rating of Buy to Neutral. For the second quarter, Realty Income had an EPS of $1.00, compared to year-ago quarter EPS of $0.97. The stock has a 52-week-high of $68.85 and a 52-week-low of $48.41. At the end of the last trading period, Realty Income closed at $50.55. According to Citigroup, the prior rating for ...Full story available on Benzinga.com

Why Shares of Zura Bio Climbed Tuesday
The Motley Fool • [email protected] (Jim Halley) • June 20, 2023

The biotech stock continued its rise in June.